FindTrial
Sign In

Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol

Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00678756
Acronym
VITAKET
Enrollment
12
Registered
2008-05-16
Start date
2008-03-31
Completion date
2009-12-31
Last updated
2010-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis Vulgaris

Keywords

Psoriasis vulgaris,, vitamin D, UVB-phototherapy, ketokonazol,, Optical Coherence Tomography,, local PASI, Nizoral

Brief summary

Exploration of antipsoriatic effects of UVB-therapy +/- CYP-inhibitor Ketokonazol on affected psoriatic skin

Interventions

DRUGKetokonazol 2% cream

twice a day at 2 times,2 out of 5 areas have to be treated for 4 weeks/7 days a week

RADIATIONUVB-radiation 311nm

3 out of 5 areas are radiated for 4 weeks every MO/DI/DO/FR starting MED orientated, intensified everytime 0,03 J/qcm

Sponsors

Technische Universität Dresden
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* age: 18- 80 * diagnosis of psoriasis vulgaris (mild- middle) * no other current antipsoriatic therapy (systemic/topical) * at least 5 psoriatic areas of 5x5 cm

Exclusion criteria

* pregnancy/nursing mothers * women in reproductive age without adequate contraception * severe and acute forms of psoriasis vulgaris * patients receiving systemic or topical antipsoroatic treatment in past 3 month * UV-therapy in past 3 month * patients having a positive anamnesis for squamous cell carcinoma, malignant melanoma, basalioma * epilepsy

Design outcomes

Primary

MeasureTime frame
PASI, PGA4 weeks

Secondary

MeasureTime frame
OCT/ultrasound- thickness of epidermis/ dermis4 weeks

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026